News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,332 Results
Type
Article (41997)
Company Profile (272)
Press Release (688047)
Multimedia
Podcasts (94)
Webinars (20)
Section
Business (205334)
Career Advice (2041)
Deals (35651)
Drug Delivery (126)
Drug Development (81730)
Employer Resources (173)
FDA (16572)
Job Trends (15052)
News (347790)
Policy (32939)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (2622)
Accelerated approval (44)
Adcomms (26)
Allergies (165)
Alliances (49731)
ALS (200)
Alzheimer's disease (1776)
Antibody-drug conjugate (ADC) (418)
Approvals (16914)
Artificial intelligence (619)
Autoimmune disease (247)
Automation (52)
Bankruptcy (362)
Best Places to Work (11687)
BIOSECURE Act (20)
Biosimilars (215)
Biotechnology (181)
Bladder cancer (182)
Brain cancer (68)
Breast cancer (704)
Cancer (5550)
Cardiovascular disease (453)
Career advice (1729)
Career pathing (41)
CAR-T (310)
CDC (55)
Celiac Disease (2)
Cell therapy (820)
Cervical cancer (44)
Clinical research (70642)
Collaboration (1984)
Company closure (4)
Compensation (1317)
Complete response letters (76)
COVID-19 (2734)
CRISPR (100)
C-suite (1044)
Cystic fibrosis (149)
Data (7394)
Decentralized trials (3)
Denatured (28)
Depression (164)
Dermatology (70)
Diabetes (558)
Diagnostics (6875)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (304)
Drug pricing (195)
Drug shortages (31)
Duchenne muscular dystrophy (268)
Earnings (91363)
Editorial (64)
Employer branding (21)
Employer resources (152)
Events (119162)
Executive appointments (1054)
FDA (20116)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (33)
Funding (1667)
Gene editing (215)
Generative AI (54)
Gene therapy (667)
GLP-1 (1033)
Government (4728)
Grass and pollen (6)
Guidances (401)
Healthcare (18996)
HIV (76)
Huntington's disease (52)
IgA nephropathy (93)
Immunology and inflammation (280)
Immuno-oncology (85)
Indications (166)
Infectious disease (3064)
Inflammatory bowel disease (208)
Inflation Reduction Act (14)
Influenza (134)
Intellectual property (279)
Interviews (320)
IPO (16670)
IRA (50)
Job creations (3681)
Job search strategy (1438)
JPM (61)
Kidney cancer (18)
Labor market (94)
Layoffs (563)
Leadership (38)
Legal (8049)
Liver cancer (98)
Longevity (30)
Lung cancer (745)
Lymphoma (415)
Machine learning (55)
Management (59)
Manufacturing (963)
MASH (178)
Medical device (13901)
Medtech (13984)
Mergers & acquisitions (20176)
Metabolic disorders (1439)
mRNA (188)
Multiple sclerosis (180)
NASH (17)
Neurodegenerative disease (401)
Neuropsychiatric disorders (105)
Neuroscience (3257)
Neurotech (1)
NextGen: Class of 2026 (6549)
Non-profit (4537)
Now hiring (74)
Obesity (679)
Opinion (286)
Ovarian cancer (202)
Pain (242)
Pancreatic cancer (272)
Parkinson's disease (356)
Partnered (33)
Patents (565)
Patient recruitment (622)
Peanut (61)
People (59559)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (21994)
Phase 2 (31086)
Phase 3 (23175)
Pipeline (7597)
Policy (308)
Postmarket research (2586)
Preclinical (9375)
Press Release (64)
Prostate cancer (283)
Psychedelics (52)
Radiopharmaceuticals (313)
Rare diseases (1018)
Real estate (5987)
Recruiting (70)
Regulatory (25221)
Reports (54)
Research institute (2432)
Resumes & cover letters (354)
Rett syndrome (34)
RNA editing (20)
RSV (88)
Schizophrenia (175)
Series A (276)
Series B (209)
Service/supplier (11)
Sickle cell disease (108)
Special edition (26)
Spinal muscular atrophy (164)
Sponsored (46)
Startups (3646)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (64)
Vaccines (1072)
Venture capital (102)
Weight loss (434)
Women's health (116)
Worklife (20)
Date
Today (159)
Last 7 days (751)
Last 30 days (2714)
Last 365 days (30440)
2026 (9606)
2025 (30262)
2024 (35311)
2023 (40170)
2022 (51263)
2021 (55805)
2020 (54159)
2019 (46616)
2018 (35121)
2017 (32204)
2016 (31629)
2015 (37698)
2014 (31500)
2013 (26543)
2012 (28727)
2011 (29386)
2010 (27446)
Location
Africa (741)
Alabama (91)
Alaska (7)
Arizona (339)
Arkansas (14)
Asia (40239)
Australia (6514)
California (12605)
Canada (3620)
China (1282)
Colorado (540)
Connecticut (545)
Delaware (380)
Europe (85977)
Florida (1893)
Georgia (403)
Hawaii (3)
Idaho (62)
Illinois (1013)
India (86)
Indiana (578)
Iowa (23)
Japan (509)
Kansas (129)
Kentucky (47)
Louisiana (39)
Maine (75)
Maryland (1513)
Massachusetts (9011)
Michigan (350)
Minnesota (691)
Mississippi (6)
Missouri (142)
Montana (33)
Nebraska (29)
Nevada (137)
New Hampshire (84)
New Jersey (3345)
New Mexico (28)
New York (3323)
North Carolina (1599)
North Dakota (8)
Northern California (6268)
Ohio (374)
Oklahoma (23)
Oregon (41)
Pennsylvania (2549)
Puerto Rico (28)
Rhode Island (50)
South America (1118)
South Carolina (83)
South Dakota (2)
Southern California (4955)
Tennessee (204)
Texas (1990)
United States (44635)
Utah (377)
Vermont (1)
Virginia (297)
Washington D.C. (81)
Washington State (1012)
West Virginia (4)
Wisconsin (120)
Wyoming (2)
730,332 Results for "teva neuroscience inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Teva Releases Q1 2026 Aide Memoire
March 20, 2026
·
2 min read
Press Releases
Teva to Present at the Upcoming Investor Conferences in March
February 25, 2026
·
3 min read
Press Releases
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
April 15, 2026
·
9 min read
Press Releases
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
February 22, 2026
·
9 min read
Press Releases
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
February 17, 2026
·
12 min read
Press Releases
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
March 20, 2026
·
2 min read
Press Releases
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
March 4, 2026
·
6 min read
Press Releases
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
March 30, 2026
·
18 min read
Obesity
Teva Brings First GLP-1 Generic for Obesity, Targets Novo’s Saxenda
In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.
August 29, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
3 min read
1 of 73,034
Next
